Circadian Rhythm & Disease

Emily BurkeBiologics, Cancer, Diabetes, Mechanism of Action, The WEEKLY

AND THE BEAT GOES ON Earlier this week, the 2017 Nobel Prize in Physiology or Medicine was awarded to three American scientists (Jeffrey Hall and Michael Rosbash, of Brandeis University, and Michael Young, of Rockefeller University) for their work in deciphering the molecular basis of circadian rhythm – the 24-hour cycle that governs the inner workings of all life on … Read More

Unpacking Digital Medicine

Emily BurkeCardiovascular Disease, Diabetes, FDA, Medical Device

CAN APPS PROGRAM BETTER HEALTH? Digital medicine is defined by the field’s pioneer Dr. Eric Tool of the Scripps Translational Science Institute (La Jolla, CA) as “the ability to digitize human beings, by a variety of means (sequencing, sensors, imaging, etc.), fully exploiting our digital infrastructure of ever-increasing bandwidth, connectivity, social networking, the Internet of all things, and health information systems.” This new field is changing the way … Read More

The Molecular Cause Of Obesity

Emily BurkeClinical Trials, Diabetes, Drug Development, Drug Targets, Mechanism of Action, Term of the Week

Targeting Fat Obesity is considered one of the most pressing public health issues of the day. According to the Center for Disease Control, 37% of adults and 17% of children in the U.S. are obese. The latest drug interventions work by attempting to suppress food intake, which has proven beneficial for some. However, there is still a large unmet need … Read More

Disrupting The Cycle

Emily BurkeClinical Trials, Deoxyribonucleic Acid (DNA), Diabetes, Drug Development, Drug Targets, Mechanism of Action, Small Molecule Drugs, The WEEKLY

Circadian Rhythms Govern More Than 24 Hours Of Your Day Overnight shift workers, students pulling an all-nighter to cram for a final exam, and business people rushing between time zones all share one thing in common: significant disruption to their circadian rhythm. This roughly 24-hour activity cycle responds primarily to light and darkness and is found in most living organisms—people, … Read More

The Emerging Proteomics Market

Emily BurkeBusiness of Biotech, Cancer, Deoxyribonucleic Acid (DNA), Diabetes, Diagnostics, Drug Targets, Genomics, Term of the Week, The WEEKLY

Picking Apart The Protein Genomics continues to be all the rage in biotech circles—with special kudos to Illumina’s (San Diego, CA) recent ability to obtain an entire human genome sequence in 24-hours for a mere thousand dollars. Our overall understanding of human DNA combined with our ability to determine individual genomes leads to better disease insight, more powerful diagnostics, and a … Read More

Stomach Stapling Paves A Pathway

Emily BurkeBiologics, Clinical Trials, Diabetes, Drug Development, Drug Targets, Mechanism of Action, The WEEKLY

Identifying Gut Proteins To Tackle Metabolic Disorders Historians of science love to tell about “eureka moments”—simple observations leading to major insight. Greek mathematician Archimedes allegedly exclaimed the original “Eureka!”—meaning “I have found it!”—upon witnessing the volume of water displaced by his body in the bathtub equaled the volume of the body part he had submerged. Medicine’s most famous eureka moment is probably the … Read More

Feeding Cancer

Emily BurkeBiotech Basics, Cancer, Clinical Trials, Deoxyribonucleic Acid (DNA), Diabetes, Drug Development, Drug Targets, Mechanism of Action, Term of the Week, The WEEKLY

The Metabolics Of Cancer Tackling cancer requires a multi-pronged strategy. Currently, many of the cancer drugs on the market work by inhibiting the signaling pathways that activate cell division. These pathways are often the root cause of cancer—a mutated gene leads to a dysfunctional signaling protein which tells the cell to divide inappropriately. In these cases, the cancer may be treated by inhibiting the … Read More

12 Biotech Concepts Everyone Should Know

Emily BurkeBiologics, Biotech Basics, Business of Biotech, Cancer, Cardiovascular Disease, Clinical Trials, Diabetes, Diagnostics, Drug Approvals, Drug Development, Drug Targets, Ebola, FDA, Genetics, Mechanism of Action, Monoclonal Antibodies, Orphan Disease, Orphan Drugs, Small Molecule Drugs, The WEEKLY

Our mission here at WEEKLY is to keep your industry knowledge up to date. We will be off Thursday, roasting our turkeys and reminding ourselves that it is not the amino acid tryptophan that makes us drowsy after a Thanksgiving feast—it is the massive carbohydrate intake! Whether you are awaiting a Thanksgiving holiday or it is business as usual, we … Read More

Cerdelga: 25 years In The Making

Emily BurkeDiabetes, Drug Approvals, FDA, Genetics, Mechanism of Action, Orphan Disease, Orphan Drugs, Small Molecule Drugs, The WEEKLY

We have a new orphan drug on the market thanks to last week’s FDA approval of Cerdelga, a small-molecule therapeutic developed by Sanofi for treatment of Gaucher’s disease. This rare genetic disorder is thought to affect around 6,000 in the United States. Regular WEEKLY readers know we like to highlight new drug approvals. After all, there are only 25 to … Read More